Attendee search 

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.

DCPrime is a Dutch biotech company which has developed a novel approach to cancer vaccines. The company’s unique platform technology consists of sustainable dendritic progenitor cells (DCOne™) and a proprietary method to expand these and to create functional mature dendritic cells (DC).

These cells, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, off-the-shelf, therapeutic products that can stimulate the patient’s immune system in a specific manner. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products.